FGF/FGFR: FGF2-mediated activation of ERK 1/2 and PLC pathway is not inhibited by sunitinib[68]MET/HGF: Hypoxia induced by VEGFR-TKIs promotes MET-depended tumor growth[76-79].GAS6/AXL: VEGFR-TKIs treatment enhances the activation of the MAPK pathway by AXL[90]. Here, FGF2 is linked to neoplasm.